Cyclo Therapeutics, Inc. Common Stock
CYTH
CYTH was delisted on the 25th of March, 2025.
13 hedge funds and large institutions have $1.38M invested in Cyclo Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
13% less funds holding
Funds holding: 15 → 13 (-2)
19% less capital invested
Capital invested by funds: $1.71M → $1.38M (-$332K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$33.2K |
| 2 |
BlackRock
New York
|
+$15.2K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$7.03K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.13K |
| 5 |
Citigroup
New York
|
+$4.31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$83K |
| 2 |
Two Sigma Advisers
New York
|
-$38K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$37.1K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3K |
| 5 |
Morgan Stanley
New York
|
-$1.05K |
CYTH Hedge Fund Activity: Q1 2022 in Review
13 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Common Stock (CYTH) for Q1 2022, worth a combined $1.38M — down 19% from $1.71M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CYTH and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $33.2K. The largest seller was Virtu Financial, exiting entirely with an estimated $83K sold.
- 13 institutional investors held Cyclo Therapeutics, Inc. Common Stock (CYTH) as of Q1 2022, down from 15 in Q4 2021.
- Funds reported $1.38M of Cyclo Therapeutics, Inc. Common Stock stock for Q1 2022, down 19% quarter-over-quarter.
- 1 fund opened new Cyclo Therapeutics, Inc. Common Stock positions in Q1 2022 and 3 closed out, a net change of -2 holders.
- The largest Cyclo Therapeutics, Inc. Common Stock buyer in Q1 2022 was Renaissance Technologies, an estimated $33.2K added.
- The largest Cyclo Therapeutics, Inc. Common Stock seller in Q1 2022 was Virtu Financial, an estimated $83K sold.
Based on aggregated 13F filings for Q1 2022.